NCT01253707 is a Phase 1 clinical trial of AMG 337 in Advanced Malignancy, sponsored by Amgen.

Who is sponsoring NCT01253707?

NCT01253707 is sponsored by Amgen.

What drugs are being tested in NCT01253707?

Interventions in NCT01253707: AMG 337.

What condition does NCT01253707 study?

NCT01253707 studies Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors.

Is NCT01253707 still recruiting?

NCT01253707 is currently completed. Last updated 7 November 2022.

Last reviewed 2022-11-07 · How we verify

NCT01253707

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Completed Phase 1 Last updated 7 November 2022

What this trial tests

Phase 1 trial testing AMG 337 in Advanced Malignancy in 111 participants. Completed in 13 December 2016.

Timeline

8 December 2010

Primary endpoint
1 October 2015

13 December 2016

Quick facts

Lead sponsor	Amgen
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	111
Start date	8 December 2010
Primary completion	1 October 2015
Estimated completion	13 December 2016
Sites	8 locations across United States

Drugs / interventions tested

AMG 337

Conditions studied

Advanced Malignancy — all drugs for Advanced Malignancy →
Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Cancer — all drugs for Cancer →
Oncology — all drugs for Oncology →

Sponsor

Amgen — full company profile →

Who can join

18 and older, any sex, with Advanced Malignancy or Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

First in human, open-label, sequential dose escalation and expansion study of AMG 337 in subjects with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive review of targeted therapy for colorectal cancer.
Xie YH, Chen YX, Fang JY. · · 2020 · cited 1162× · PMID 32296018 · DOI 10.1038/s41392-020-0116-z
Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F, Rabe DC, Bottaro DP. · · 2012 · cited 180× · PMID 22530990 · DOI 10.1517/14728222.2012.680957
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Kwak EL, Ahronian LG, Siravegna G, Mussolin B, et al · · 2015 · cited 140× · PMID 26432108 · DOI 10.1158/2159-8290.cd-15-0748
Targeted therapies for gastric cancer: failures and hopes from clinical trials.
Apicella M, Corso S, Giordano S. · · 2017 · cited 102× · PMID 28915702 · DOI 10.18632/oncotarget.14825
Tyrosine Kinase Receptors in Oncology.
Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, et al · · 2020 · cited 72× · PMID 33198314 · DOI 10.3390/ijms21228529
Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.
Venepalli NK, Goff L. · · 2013 · cited 52× · PMID 23606971 · DOI 10.1155/2013/341636
MET inhibitors in combination with other therapies in non-small cell lung cancer.
Padda S, Neal JW, Wakelee HA. · · 2012 · cited 23× · PMID 25806189 · DOI 10.3978/j.issn.2218-6751.2012.10.08
Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.
Zhang Z, Li D, Yun H, Tong J, et al · · 2022 · cited 11× · PMID 35978812 · DOI 10.3389/fonc.2022.923260

Verify or expand the search:

Other trials of AMG 337

Trials testing the same drug.

NCT03132155 — QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma · Phase 2 · terminated
NCT03147976 — QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors · Phase 2 · withdrawn
NCT02096666 — A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects · Phase 1, PHASE2 · completed

Other recruiting trials for Advanced Malignancy

Currently open trials in the same condition.

NCT07238075 — ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers · Phase 1 · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01253707 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 7 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01253707.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing